Opium (Opioid) Addiction - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 99
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O44D6D3C48BEN
Leaflet:

Download PDF Leaflet

Opium (Opioid) Addiction - Pipeline Review, H2 2016
Opium (Opioid) Addiction - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2016’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
  • The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Opium (Opioid) Addiction Overview
Therapeutics Development
Pipeline Products for Opium (Opioid) Addiction - Overview
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis
Opium (Opioid) Addiction - Therapeutics under Development by Companies
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes
Opium (Opioid) Addiction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Opium (Opioid) Addiction - Products under Development by Companies
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
Alkermes Plc
Aoxing Pharmaceutical Company, Inc
BioDelivery Sciences International, Inc.
Camurus AB
Foresee Pharmaceuticals, LLC
Heron Therapeutics, Inc.
Indivior Plc
INSYS Therapeutics, Inc.
Omeros Corporation
Pfizer Inc.
Relmada Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd.
Titan Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.
Opium (Opioid) Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride depot - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride long acting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-5006739 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
samidorphan l-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEV-90109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Opium Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opium (Opioid) Addiction - Dormant Projects
Opium (Opioid) Addiction - Discontinued Products
Opium (Opioid) Addiction - Product Development Milestones
Featured News & Press Releases
Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers
Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers
Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US
Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence
Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers
Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers
Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers
Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence
Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting
Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence
Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers
Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine
Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers
Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Opium (Opioid) Addiction, H2 2016
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2016
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2016
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2016
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2016
Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2016
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Opium (Opioid) Addiction - Dormant Projects, H2 2016
Opium (Opioid) Addiction - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Opium (Opioid) Addiction, H2 2016
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Alkermes Plc
Aoxing Pharmaceutical Company, Inc
BioDelivery Sciences International, Inc.
Camurus AB
Foresee Pharmaceuticals, LLC
Heron Therapeutics, Inc.
Indivior Plc
INSYS Therapeutics, Inc.
Omeros Corporation
Pfizer Inc.
Relmada Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd.
Titan Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.
Skip to top


Alcohol Addiction - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 138 pages

Ask Your Question

Opium (Opioid) Addiction - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: